Welcome to our dedicated page for UTPD news (Ticker: UTPD), a resource for investors and traders seeking the latest updates and insights on UTPD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UTPD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UTPD's position in the market.
Estrella Biopharma has received FDA clearance for its IND application for EB103, a T-cell therapy aimed at treating relapsed/refractory B-cell non-Hodgkin lymphoma, including patients with severe unmet medical needs. The Phase I/II clinical trial, named Starlight-1, is expected to commence in the second half of 2023, focusing on patient safety, tolerability, and anti-cancer activity of EB103. The trial will initially enroll patients at UC Davis Health. EB103 employs Eureka's ARTEMIS® technology to target CD19, aiming to benefit patients who are often excluded from other trials due to severe side effects.
